Nurzigma (pridopidine)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- pridopidine
- Company
- Prilenia Therapeutics B.V.
- Status
- Application withdrawn
- Therapeutic area
- Huntington Disease
- CHMP opinion
- Thu 24 Jul 2025
- Designations
- Orphan
- Application
- EMEA/H/C/006261
- ATC
- N07
- Official record
- www.ema.europa.eu
Indication
Treatment of Huntington's disease
Regulatory milestones
Fri 07 Nov 2025🇪🇺 Application withdrawn (EU)
Nurzigma (pridopidine): EU application withdrawn
Follow Nurzigma
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.